financetom
CLPT
financetom
/
Healthcare
/
CLPT
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
ClearPoint Neuro, Inc.CLPT
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States.

The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance.

It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain.

It has license and collaboration agreements with Clinical Laserthermia Systems AB, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco.

The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020.

ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Latest News >
Japan's Nikkei ends lower on worries about US-China trade tension, stronger yen
Japan's Nikkei ends lower on worries about US-China trade tension, stronger yen
Jun 2, 2025
(Updates with closing prices) TOKYO, June 2 (Reuters) - Japan's Nikkei share average ended lower on Monday amid worries over trade tensions between the U.S. and China, and a stronger yen, which hurt automakers. The Nikkei fell 1.3% to 37,470.67 and the broader Topix slipped 0.87% to 2777.29. Investors were worried about rising uncertainties about trade issues, said Shoichi Arisawa,...
Tesla's sales in Sweden fall 53.7% year-on-year in May
Tesla's sales in Sweden fall 53.7% year-on-year in May
Jun 2, 2025
STOCKHOLM (Reuters) -Tesla's new car sales in Sweden fell 53.7% in May from a year earlier to 503 vehicles, registration data from Mobility Sweden showed on Monday. ...
Novartis' Pluvicto shown to slow prostate cancer in earlier setting
Novartis' Pluvicto shown to slow prostate cancer in earlier setting
Jun 2, 2025
FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage for a drug technology that the drugmaker has pioneered. The Swiss drugmaker reported a late-stage trial showed a clinically meaningful benefit in progression-free survival with a positive...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Copyright 2023-2025 - www.financetom.com All Rights Reserved